Skip to content
Sunday 9 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

pharmaceuticals

  • US drug giant Pfizer beats GSK to UK government contract for 4.9m vaccine shots

    June 25, 2024

    Pfizer has beaten GSK to win a contract to supply millions of doses of a new respiratory vaccine in the UK after the government snubbed the local drugmaker.

  • Alliance Pharma sees profit and revenue spike amid ongoing uncertainty

    June 19, 2024

    Alliance Pharma has hailed its strong second half performance for helping it to record sales and additional profit expansion in its preliminary results despite the healthcare group having delayed its audited results three times this year.

  • GSK: Good news for pharma giant as approval granted to expand vaccine use

    June 10, 2024

    The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.

  • Angle: Pharma firm’s share price plunges after missing market forecasts

    June 5, 2024

    Angle also today announced a plan to raise about £8.5m through a combination of new share placements and subscriptions.

  • Astrazeneca swallows up Canada-based Fusion Pharmaceuticals in £1.5bn move

    June 5, 2024

    Astrazeneca has completed its $2bn (£1.5bn) acquisition of Canada-based Fusion Pharmaceuticals, in a deal first announced in March.

  • GSK: How much could the Zantac lawsuits cost?

    June 3, 2024

    Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.

  • Boots: Profit surges at British icon as owner mulls £7bn London float

    May 29, 2024

    Historic pharmacy chain Boots has reported a surge in its pre-tax profit for its latest financial year amid reports its owner is considering a £7bn float in London.

  • Astrazeneca to build huge new cancer drug plant in Singapore

    May 20, 2024

    Astrazeneca has said it will invest $1.5bn (£1.2bn) to build a manufacturing facility in Singapore to produce antibody drug conjugates (ADCs), a next-generation cancer treatment.

  • Ozempic and Wegovy: What happens when a drug goes viral?

    May 18, 2024

    Novo Nordisk's Wegovy and Ozempic have been heralded as the solution to the world's growing obesity problems. But when celebrities and influencers misuse them and start documenting their weight loss journeys online, should we take stock?

  • Haleon posts healthy first quarter update after UK job cuts

    May 1, 2024

    Revenue at Haleon was up in the first quarter despite its announcement yesterday that it would cut over 400 jobs in the UK, as the consumer healthcare firm posted a quarterly update in line with expectations.

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Page 20
  • Next

Trending Articles

  • Thames Water faces fresh threat to survival after pensions regulation breach

  • PwC’s Embankment HQ to get major makeover ahead of Canary Wharf move

  • Family feud: London estate agent Winkworth sues chair over plot with wife to oust son from board

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

  • A tribute to wine legend Matthew Jukes by his friend Libby Brodie

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook